Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus.

Détails

Ressource 1Télécharger: 24652665.pdf (588.10 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_B279E13B1B71
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus.
Périodique
Swiss Medical Weekly
Auteur(s)
Wuerzner G., Muller O., Erne P., Cook S., Sudano I., Lüscher T.F., Noll G., Kaufmann U., Rickli H., Waeber B., Kaiser C., Sticherling C., Pechère-Bertschi A., Baumgartner I., Jacob A.L., Burnier M., Qanadli S.D., Interventional Radiology
Collaborateur(s)
Swiss Society of Hypertension, Swiss Society of Cardiology, Swiss Society of Angiology, Swiss Society of Cardiovascular
Contributeur(s)
Interventional Radiology
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
2014
Volume
144
Pages
w13913
Langue
anglais
Notes
Publication types: Journal Article ; Practice Guideline ; Research Support, Non-U.S. Gov't ; Review Publication Status: epublish
Résumé
Transcatheter (or percutaneous) renal denervation is a novel technique developed for the treatment of resistant hypertension. So far, only one randomised controlled trial has been published, which has shown a reduction of office blood pressure. The Swiss Society of Hypertension, the Swiss Society of Cardiology, The Swiss Society of Angiology and the Swiss Society of Interventional Radiology decided to establish recommendations to practicing physicians and specialists for good clinical practice. The eligibility of patients for transcatheter renal denervation needs (1.) confirmation of truly resistant hypertension, (2.) exclusion of secondary forms of hypertension, (3.) a multidisciplinary decision confirming the eligibility, (4.) facilities that guarantee procedural safety and (5.) a long-term follow-up of the patients, if possible in cooperation with a hypertension specialist. These steps are essential until long-term data on safety and efficacy are available.
Mots-clé
Antihypertensive Agents/therapeutic use, Arterial Pressure, Consensus, Drug Resistance, Humans, Hypertension/drug therapy, Hypertension/surgery, Kidney/innervation, Patient Selection, Switzerland, Sympathectomy/adverse effects, Sympathectomy/methods
Pubmed
Open Access
Oui
Création de la notice
11/07/2014 13:10
Dernière modification de la notice
20/08/2019 16:21
Données d'usage